Nicole Jackson
Psychiatric/Mental Health · Dover, DENPI 1366974628
Payments from drug & device makers
Across 28 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$129
- Otsuka America Pharmaceutical, Inc.$123
- Lundbeck LLC$66
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$62
- AbbVie$53
- Takeda Pharmaceuticals U.S.A., Inc.$48
- plus $132 from 6 others
What the payments were for
- Food & beverage$56592%
- Education$478%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| Otsuka America Pharmaceutical, Inc. | 6 | $123 |
| Lundbeck LLC | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $62 |
| AbbVie | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Indivior Inc. | 2 | $34 |
| Novo Nordisk | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$612 in reported general payments places this provider in the 50th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $11,590 |
| AmbienZolpidem Tartrate | 13 | $8,242 |
| Quetiapine Fumarate | 132 | $3,051 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 61 | $1,899 |
| Duloxetine Hcl | 65 | $1,321 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,210 |
| Lurasidone Hcl | 29 | $1,155 |
| Oxcarbazepine | 18 | $1,143 |
| Buspirone Hcl | 61 | $1,058 |
| Trazodone Hcl | 77 | $997 |
| Bupropion XlBupropion Hcl | 46 | $737 |
| Clonazepam | 114 | $697 |
| Hydroxyzine Hcl | 14 | $547 |
| Lamotrigine | 51 | $494 |
| Divalproex Sodium | 13 | $481 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Dover
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
- Jeremy LegatesDover$3K
- Melchizedec BosireDover$3K
- Sherri ClarkDover$3K
- Maureen DarlingDover$3K
- Heather FryeDover$3K
- Morgan WebbDover$2K
- Ronald TyreeWilmington$59K
- Kameka HartNewark$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.